Experienced in Primary Immunodeficiency (PID)

Aurelie Du Thanh

Montpellier, FR 
Experienced in Primary Immunodeficiency (PID)
Montpellier, FR 
OverviewLocationsClinical Research

Overview

Aurelie Du Thanh practices in Montpellier, France. Ms. Du Thanh is rated as an Experienced expert by MediFind in the treatment of Primary Immunodeficiency (PID). Her top areas of expertise are Hives, Angioedema, Hereditary Angioedema, and Porphyria Cutanea Tarda.

Her clinical research consists of co-authoring 19 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 2 clinical trials in the study of Primary Immunodeficiency (PID).

Gender
Female

Locations

Montpellier, France
Other Locations
Paris, France
AP HP, CHU Henri Mondor
Creteil, France
Lille, 59000, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Icatibant Outcome Survey (IOS) Registry
Icatibant Outcome Survey (IOS) Registry
Enrollment Status: Completed
Publish Date: October 28, 2024
Retrospective, Observational Chart Review Study Evaluating Clinical Effectiveness and Disease/Treatment Management Among Patients Who Initiated Long-term Prophylaxis With Takhzyro® in a Real-world Setting
Retrospective, Observational Chart Review Study Evaluating Clinical Effectiveness and Disease/Treatment Management Among Patients Who Initiated Long-term Prophylaxis With Takhzyro® in a Real-world Setting
Enrollment Status: Completed
Publish Date: January 13, 2023
View 1 Less Clinical Trial

19 Total Publications

Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.
Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.
Journal: Melanoma research
Published: March 28, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Du Thanh's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile